Article Detail - JE Part B
MolDX: Blood Product Molecular Antigen Typing - Effective December 06, 2020
This Local Coverage Determination (LCD) has completed the Open Public Meeting and comment period and is now finalized under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV). Responses to comments received may be found as a link at the bottom of the final LCD.
Medicare Coverage Database (MCD) Number/Contractor Determination Number: L38331
LCD Title: MolDX: Blood Product Molecular Antigen Typing
FORMERLY: MolDX: Erythrocyte Molecular Antigen Typing
Effective Date: December 06, 2020
Summary of LCD: Limited-coverage for molecular phenotyping of blood product antigens performed by Food and Drug Administration (FDA) approved tests in line with their FDA-approved use for patients who are required or expected to require a blood product transfusion (Red Blood Cells, Platelets or White Blood Cells) meeting at least one of the following criteria: Long term, frequent transfusions anticipated to prevent the development of alloantibodies or autoantibodies or other serologic reactivity that impedes the exclusion of clinically significant alloantibodies.
Visit the Future LCDs webpage to access this LCD.
Last Updated Thu, 22 Oct 2020 17:41:56 +0000